결핵 진단 시장 예측 : 제품 유형, 검사 유형, 질환 진행 단계, 최종사용자 및 지역별 분석(-2034년)

According to Stratistics MRC, the Global Tuberculosis Diagnostics Market is accounted for $2.58 billion in 2026 and is expected to reach $4.64 billion by 2034 growing at a CAGR of 7.6% during the forecast period. Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis and it mainly attacks the lungs, spine, and brain of the patients. Tuberculosis diagnostics provide objective and precise identification of TB infection. They help differentiate TB from other respiratory diseases with similar symptoms, reducing misdiagnosis and unnecessary treatments.

According to the WHO Global Tuberculosis report 2022, in 2021, approximately 10.6 million individuals fell ill with tuberculosis globally, representing 4.5% rise from 10.1 million cases reported in 2020.

Market Dynamics:

Driver:

Drug-resistant TB

The emergence of drug-resistant strains, such as multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), has created a need for accurate and rapid diagnostic tests. Drug-resistant TB strains do not respond to the standard first-line anti TB medications, making their detection and appropriate treatment critical. Traditional diagnostic methods may not be effective in identifying drug-resistant strains, leading to delayed or ineffective treatment, increased transmission, and poor patient outcomes. As a result, there is a growing demand for advanced diagnostics that can accurately detect drug-resistant TB.

Restraint:

High cost

Advanced diagnostic technologies, such as molecular tests and genotypic assays, often come with a higher price tag compared to traditional methods like sputum smear microscopy. The cost of these tests includes not only the test kits but also the equipment, laboratory infrastructure, and skilled personnel required for their implementation. Therefore, high costs may deter healthcare providers from implementing more advanced and precise diagnostic techniques, impeding the growth of the market.

Opportunity:

Advanced diagnostic technologies

The utilization of molecular techniques, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), allows for the detection of TB with enhanced sensitivity, enabling diagnosis even in cases with low bacterial loads. Additionally, improvements in point-of-care testing bring diagnostics closer to the patient. This is especially advantageous in settings with limited resources because it shortens the time between starting treatment and receiving results. Therefore, these advanced diagnostic technologies accelerate market growth.

Threat:

Stigma

Misconceptions regarding the mode of transmission, fear of infection, and associations with poverty or marginalized groups are some of the factors that contribute to the stigma surrounding tuberculosis. However, this stigma can lead to reluctance among individuals to disclose their symptoms, seek healthcare, or undergo TB diagnostic testing. People may be unable to receive TB diagnostic services because of fear of social exclusion, discrimination, or unfavourable societal perceptions. This can postpone diagnosis and contribute to the disease's spread. These factors hamper market demand.

Covid-19 Impact

The COVID-19 pandemic has had a significant impact on the tuberculosis diagnostics market. While it initially disrupted healthcare systems, diverting resources away from TB diagnostics, it also highlighted the importance of robust diagnostic infrastructure. Long-term benefits for TB diagnostics could result from increased awareness of the need for strengthening healthcare systems as the pandemic fades. Furthermore, COVID-19 may have accelerated advancements in telemedicine and digital health, which could improve the capacity for tuberculosis diagnosis.

The diagnostic laboratory methods segment is expected to be the largest during the forecast period

The diagnostic laboratory methods segment is estimated to hold the largest share. Most hospitals and clinics globally provide culture-based tests as well as smear microscopy. Due to this, they are a viable choice for tuberculosis diagnosis for patients who might not have access to more sophisticated diagnostic procedures. Moreover, while newer tests, such as nucleic acid amplification tests (NAATs), are becoming more widely available, smear microscopy and culture-based tests are still considered to be the most accurate tests for diagnosing tuberculosis.

The sputum smear microscopy segment is expected to have the highest CAGR during the forecast period

The sputum smear microscopy segment is anticipated to have lucrative growth during the forecast period. It is a simple and cost-effective technique used to detect acid-fast bacilli (AFB) in sputum samples, aiding in the diagnosis of pulmonary TB. Sputum smear microscopy is widely available, even in resource-limited settings, as it does not require sophisticated laboratory infrastructure or expensive equipment. Moreover, it provides rapid results, enabling healthcare providers to initiate TB treatment promptly, reducing transmission, and improving patient outcomes.

Region with largest share:

Asia Pacific dominated the market and accounted for the largest market share due to its high burden as well as the rapid proliferation of this disease. The rising rates of tuberculosis in several of the countries in this region are one of the primary drivers of the increase in market revenue. Furthermore, the high mortality rate and low human development index in this region are important factors that support the growth in market revenue. Bangladesh, China, India, Indonesia, Pakistan, and the Philippines are among the affected nations in this region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, owing to the rising prevalence of tuberculosis among adults and children. Medical research institutes in this region are discovering an increasing number of benefits associated with pathogen-specific metabolic pathways. This could serve as a substitute for the existing techniques that focus on the detection of pathogen immune responses, bacterial growth, or bacterial nucleic acid amplification. Additionally, AI and nanotechnology combined significantly aid in improving the tuberculosis diagnosis process among patients in North America.

Key players in the market

Some of the key players in the Tuberculosis Diagnostics Market include Becton Dickinson and Company, Qiagen NV, Thermo Fisher Scientific Inc., Oxford Immunotec Ltd., Hoffmann-La Roche Ltd., Hologic Inc., BioMerieux SA, Akonni Biosystems Inc., Cepheid Inc., Alere Inc., PAR Pharmaceuticals, Hain Life Science and Lionex GmbH.

Key Developments:

In February 2022 - QIAGEN announced that its QuantiFERON tuberculosis testing solution received the approval of the fourth generation of a modern gold standard test in China.

In March 2022, Thermo Fisher Scientific Inc. launched the SeqStudio Flex Series Genetic Analyzer for research & development of infectious disease detection, which is expected to expand the company's product portfolio in the market.

Product Types Covered:

• Sputum Smear Microscopy
• Culture-Based Diagnostics
• Rapid Molecular Diagnostics
• Other Product Types

Test Types Covered:

• Detection of Latent Infection
• Radiographic Method
• Nucleic Acid Testing
• Phage Assay
• Diagnostic Laboratory Methods
• Detection of Drug Resistance
• Cytokine Detection Assay
• Other Test Types

Disease Stages Covered:

• Active Tuberculosis
• Latent Tuberculosis

End Users Covered:

• Physician's Office Laboratories
• Hospitals and Diagnostic Laboratories
• Reference Laboratories
• Academics and Research Facilities
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Tuberculosis Diagnostics Market, By Product Type

• 5.1 Introduction
• 5.2 Sputum Smear Microscopy
• 5.3 Culture-Based Diagnostics
• 5.4 Rapid Molecular Diagnostics
• 5.5 Other Product Types

6 Global Tuberculosis Diagnostics Market, By Test Type

• 6.1 Introduction
• 6.2 Detection of Latent Infection
• 6.3 Radiographic Method
• 6.4 Nucleic Acid Testing
• 6.5 Phage Assay
• 6.6 Diagnostic Laboratory Methods
• 6.7 Detection of Drug Resistance
• 6.8 Cytokine Detection Assay
• 6.9 Other Test Types

7 Global Tuberculosis Diagnostics Market, By Disease Stage

• 7.1 Introduction
• 7.2 Active Tuberculosis
• 7.3 Latent Tuberculosis

8 Global Tuberculosis Diagnostics Market, By End User

• 8.1 Introduction
• 8.2 Physician's Office Laboratories
• 8.3 Hospitals and Diagnostic Laboratories
• 8.4 Reference Laboratories
• 8.5 Academics and Research Facilities
• 8.6 Other End Users

9 Global Tuberculosis Diagnostics Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Becton Dickinson and Company
• 11.2 Qiagen NV
• 11.3 Thermo Fisher Scientific Inc.
• 11.4 Oxford Immunotec Ltd.
• 11.5 Hoffmann-La Roche Ltd.
• 11.6 Hologic Inc.
• 11.7 BioMerieux SA
• 11.8 Akonni Biosystems Inc.
• 11.9 Cepheid Inc.
• 11.10 Alere Inc.
• 11.11 PAR Pharmaceuticals
• 11.12 Hain Life Science.
• 11.13 Lionex GmbH